Navarro A, Brooks A
Hepatobiliary Surgery and Major Trauma, Nottingham University Hospitals NHS Trust and East Midlands Major Trauma Centre, Nottingham, UK.
Eur J Trauma Emerg Surg. 2015 Oct;41(5):493-500. doi: 10.1007/s00068-014-0441-4. Epub 2014 Aug 26.
Uncontrolled haemorrhage as a result of trauma remains a significant surgical challenge, accounting for approximately 25-40% of trauma-related mortality. A wide range of local internal haemostatic agents have been developed to help achieve intra-cavity control of bleeding, with choice of agent influenced by the circumstances and nature of the haemorrhage. Trauma patients are frequently coagulopathic, so products that incorporate pro-coagulant technology and thereby act independently of the clotting cascade may be more effective in these settings. A range of products that utilise thrombin and fibrinogen to promote local haemostasis at intra-cavity bleeding points are available or in development, including fibrin glues (e.g. Tisseel®/Tissucol® and Evicel®/Crosseal®/Quixil®), fibrin sealant patches (e.g. TachoSil®) and products based on a gelatin-thrombin haemostatic matrix (e.g. FloSeal®).
This systematic review was performed to assess all peer-reviewed evidence of product efficacy.
Fibrin sealant patches have shown haemostatic efficacy in a variety of surgical procedures and appear to offer practical advantages over liquid fibrin glues. Existing evidence suggests that patch products enable delivery of pro-coagulants to defined areas with less chance of dilution and/or displacement by blood flow, but they require a pressure buttress for a suitable amount of time to achieve good results after trauma.
Our experience, supported by other reports in the literature, suggests the use of such fibrin patches may provide an effective option in helping to control haemorrhage after trauma. However, there is a general paucity of clinical data for intra-cavity haemostatic agent use, with the majority of data being based on animal models and case reports. Further clinical evidence, ideally including comparative studies between different agents, would be beneficial in helping guide surgeon choice to the most appropriate products to use in trauma settings.
创伤导致的失控性出血仍然是一项重大的外科挑战,约占创伤相关死亡率的25%-40%。人们已研发出多种局部内用止血剂,以帮助实现腔内出血控制,止血剂的选择受出血情况和性质影响。创伤患者常伴有凝血功能障碍,因此采用促凝血技术且独立于凝血级联反应发挥作用的产品在这些情况下可能更有效。一系列利用凝血酶和纤维蛋白原促进腔内出血点局部止血的产品已上市或正在研发中,包括纤维蛋白胶(如Tisseel®/Tissucol®和Evicel®/Crosseal®/Quixil®)、纤维蛋白封闭剂贴片(如TachoSil®)以及基于明胶-凝血酶止血基质的产品(如FloSeal®)。
本系统评价旨在评估所有经同行评审的关于产品疗效的证据。
纤维蛋白封闭剂贴片在多种外科手术中已显示出止血效果,且似乎比液体纤维蛋白胶具有实际优势。现有证据表明,贴片产品能够将促凝血剂输送到特定区域,被血流稀释和/或冲走的可能性较小,但创伤后需要在适当时间内施加压力支撑以取得良好效果。
我们的经验以及文献中的其他报道表明,使用此类纤维蛋白贴片可能为帮助控制创伤后出血提供一种有效选择。然而,关于腔内止血剂使用的临床数据普遍匮乏,大多数数据基于动物模型和病例报告。进一步的临床证据,理想情况下包括不同药物之间的对比研究,将有助于指导外科医生选择创伤情况下最合适使用的产品。